3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
22
Pancreatic Neoplasms
9
Colonic Neoplasms
8
Burkitt Lymphoma
8
Stomach Neoplasms
5
Neoplasm Metastasis
5
Esophageal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Rectal Neoplasms
4
Cholangiocarcinoma
4
Adenocarcinoma Of Esophagus
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
3
Ovarian Neoplasms
3
Neoplasms
3
Lung Neoplasms
3
Endometrial Neoplasms
3
Adenocarcinoma
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Leukemia, Biphenotypic, Acute
2
Down Syndrome
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Small Bowel Adenocarcinoma
1
Interventions
lutetium Lu 177 dotatate
1
encorafenib
1
durvalumab
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Gemcitabine
1
Folfox protocol
1
Fluorouracil
1
Cisplatin
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Leucovorin
×
30 days
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts